Jonathan Lim, M.D., is a physician-turned-venturepreneur who has founded, funded and led multiple biotechnology startups that have brought life-changing therapeutics to patients globally while collectively generating approximately $10 billion in shareholder value. Jonathan joined ARCH Venture Partners in December 2018 to help build impactful companies founded on exceptional science, such as Erasca, which he co-founded in July 2018 with the mission to erase cancer and serves as Chairman, CEO, and Co-Founder; Boundless Bio, where he is Chairman and Co-Founder; and Maze Therapeutics, where he is a Board Director. He also is the Managing Partner and Founder of City Hill Ventures.
Prior to Erasca, Jonathan’s most recent operational role was with precision oncology company Ignyta (RXDX), which he co-founded in 2011 and served as Chairman, President and CEO until its acquisition by Roche in 2018. He also previously served as Chairman and Co-founder of Bonti from 2015 until its 2018 acquisition by Allergan; Chairman, CEO and Co-founder of Eclipse Therapeutics from 2011 to its 2012 acquisition by Bionomics; and President, CEO and Chairman-then-Director of Halozyme Therapeutics (HALO) from 2003 to 2010. Earlier in his career, Jonathan was a management consultant at McKinsey & Company, an NIH Postdoctoral Fellow at Harvard Medical School and Dana Farber Cancer Institute, and a general surgery resident at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. He holds B.S. and M.S. degrees from Stanford University, an M.D. from McGill University and an M.P.H. from Harvard University.